drugset / Trial / NCT01195675
Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects
RandomizedCrossoverDouble-blindTreatment
Summary
The objective of this study is to demonstrate that BI 10773 does not prolong the QT(c) interval more than placebo
Timeline
- Start
- 2010-08
- Primary completion
- 2010-11
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 25 mg | Oral |
| Subject | Empagliflozin | Small molecule | 200 mg | Oral |
| Comparator | Moxifloxacin | Small molecule | 400 mg | Oral |
Indications
No indication recorded.